MedTrace Logo

Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects

NCT01309854 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-07-07

No results posted yet for this study

Summary

The purpose of this study is to investigate the drug interaction between fostamatinib and pioglitazone by comparing the safety, tolerability and plasma concentration of pioglitazone when administered alone and with fostamatinib in healthy subjects.

Conditions

  • Rheumatoid Arthritis
  • Healthy Volunteers
  • Pharmacokinetics
  • Pioglitazone
  • Drug-drug Interaction
  • Amount of Pioglitazone in Blood

Interventions

DRUG

fostamatinib

oral tablets, 100mg (2 X 50mg) twice daily for 8 days

DRUG

pioglitazone

oral tablets, 30mg single dose per period

Sponsors & Collaborators

Principal Investigators

  • Mark Layton, MD, MRCP · AstraZeneca

  • Carlos Prendes, MD · Quintiles Overland Park, Phase 1 Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01309854 on ClinicalTrials.gov